Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

Glaukos shares gained 36.8% over six months, versus 8% industry growth, amid strong commercial and clinical progress. Q2 sales rose approximately 50% year over year to a record $185.6 million, and the company raised 2026 revenue guidance to $680–$700 million from $620–$635 million; its 14-cent loss per share beat consensus by 50%. Positive Epioxa and iDose TR results and expanding commercial access support growth, though reimbursement uncertainty, launch timing, and development costs remain risks.

Analysis

The key issue is conversion, not addressable-market reach: payer access and treatment-center coverage do not establish paid starts, repeatable physician workflow, or net realized revenue. Epioxa’s J-code transition may temporarily obscure demand, so watch treated-patient volumes and net sales rather than coverage-life announcements. For iDose TR, Medicare policy is the more consequential near-term swing factor: restrictions could slow adoption and weaken the growth engine before pipeline programs can contribute. The dependence of growth on iDose makes any reimbursement or utilization miss disproportionately important to the consolidated trajectory.

Over the next 1–3 months, the next evidence is commercial execution and payer policy; clinical pipeline milestones are mostly 6–18 month optionality, not a near-term earnings backstop. Positive cataract-surgery data may broaden physician consideration, but adoption still depends on coverage, workflow, and demonstrated real-world use. Alcon and established glaucoma drug providers could face incremental competitive pressure if interventional treatment gains share, though the article provides no evidence yet of material displacement.

Contrarian view: the rally may be treating access infrastructure and early clinical evidence as if they were already durable sales. Conversely, the market may underweight the value of a differentiated platform if quarterly adoption confirms. Without valuation, short-interest, and option-pricing data, avoid a large momentum chase. Falsify the constructive thesis if management trims guidance, iDose adoption stalls, or Medicare coverage becomes materially restrictive; confirmation would be sequential commercial growth without a guidance reset.

Key Decisions for Investors

• Do not chase GKOS after the sharp run. Consider a small, staged long only on a pullback or after the next report confirms continued iDose uptake and Epioxa paid-treatment conversion; size for reimbursement risk.
• Set an event alert on Medicare coverage decisions and monitor quarterly iDose revenue/utilization. A restrictive policy or stalled adoption is a reason to reduce or exit the long thesis, not merely wait for pipeline news.
• Treat Epioxa coverage figures as a leading indicator, not revenue proof. Require evidence of treatment volumes and net sales conversion before underwriting the launch as a durable growth leg.
• Keep GLK-321, PRESERFLO, and retinal biologics as longer-dated optionality; do not capitalize them as near-term earnings support absent regulatory progress and commercialization evidence.